146,059 members

Skip to content. | Skip to navigation


NICE draft guidance


Start sharing

If you've got news you'd like to share, let us know and we'll consider it for our news section.

NICE draft guidance

NICE has issued draft guidance for public consultation which does not recommend siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).

Please click here to find out more.